SHIRLEY MOORJANI: Open Payments
NPI 1952844664 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,537 in 97 payments from 14 companies in 2025. Trend: 2023 $1,851 · 2024 $1,599 · 2025 $2,537
Food & beverage: $2,537
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $556 |
| E.R. Squibb & Sons, L.L.C. | 10 | $436 |
| Alkermes, Inc. | 14 | $348 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $346 |
| Neurocrine BioSciences, Inc. | 15 | $296 |
| Teva Pharmaceuticals USA, Inc. | 10 | $208 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| ABBVIE INC. | 4 | $67 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Tris Pharma Inc | 1 | $32 |
Products named: COBENFY, REXULTI, ARISTADA, CAPLYTA, INGREZZA, AUSTEDO XR, ABILIFY MAINTENA, FANAPT.
Industry payments across NV — which companies pay providers there.
